ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

MRKR Marker Therapeutics Inc

3.63
-0.02 (-0.55%)
After Hours
Last Updated: 16:30:00
Delayed by 15 minutes

Period:

Draw Mode:

Volume 32,652
Bid Price 3.52
Ask Price 3.63
News -
Day High 3.69

Low
0.6706

52 Week Range

High
9.6799

Day Low 3.40
Company Name Stock Ticker Symbol Market Type
Marker Therapeutics Inc MRKR NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.02 -0.55% 3.63 16:30:00
Open Price Low Price High Price Close Price Prev Close
3.68 3.40 3.69 3.63 3.65
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
255 32,652 $ 3.53 $ 115,263 - 0.6706 - 9.6799
Last Trade Time Type Quantity Stock Price Currency
16:00:08 1 $ 3.63 USD

Marker Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
32.18M 8.89M - 9.01M -29.93M -3.37 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Marker Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No MRKR Message Board. Create One! See More Posts on MRKR Message Board See More Message Board Posts

Historical MRKR Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.914.113.403.8219,448-0.28-7.16%
1 Month4.614.893.404.1515,042-0.98-21.26%
3 Months2.876.15682.80164.6688,9290.7626.48%
6 Months5.606.79992.404.5958,761-1.97-35.18%
1 Year2.209.67990.67062.54277,7161.4365.00%
3 Years25.0036.500.670614.84835,904-21.37-85.48%
5 Years62.9091.700.670620.18658,174-59.27-94.23%

Marker Therapeutics Description

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.

Your Recent History

Delayed Upgrade Clock